Pembrolizumab

Acral Lentiginous Melanoma

Yonsei Universitymonoclonal_antibodyPhase 2Active

BB

65/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 51/ 100
Competitive Position: 89/ 100

Competitive context

18 Active assets in the Acral Lentiginous Melanoma cohort.

Asset / Sponsor	Phase	Rating
Nilotinib Institute of Cancer Research, United Kingdom	Phase 2	B
Nivolumab Fred Hutchinson Cancer Center	Phase 2	B
Rivoceranib Peking University Cancer Hospital & Institute	Phase 3	B
Imatinib National Cancer Institute (NCI)	Phase 2	B
Catequentinib Qilu Hospital of Shandong University	Phase 2	B

View all 28 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerActive

BBB

Indicative · Phase 2

72 / 100

estrogen-receptor negative breast cancerActive

BB

Indicative · Phase 2

71 / 100

progesterone-receptor negative breast cancerActive

BB

Indicative · Phase 2

71 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.